- Title
- The diverse landscape of genitourinary cancer immunotherapy
- Creator
- Gedye, Craig
- Relation
- Cancer Forum Vol. 42, Issue 1, p. 29-39
- Publisher
- Cancer Council Australia
- Resource Type
- journal article
- Date
- 2018
- Description
- Prostate, bladder, kidney, testis and penile cancers cause over 10% of all cancer deaths, and standard treatments are largely palliative in advanced or metastatic disease. Cancer immunotherapy has an established and rapidly expanding role in the management of genitourinary cancers, but the different cancers also give insights across the landscape of immunotherapy. Renal cancers can often have a well-established immune response, and can be poised for impressive responses to checkpoint immunotherapy. Combination immunotherapy will likely improve these 'fertile plains' further. The 'desert' of prostate cancer immunotherapy is currently hostile and unappealing, but vaccine strategies to increase immune recognition and novel checkpoint inhibitors are being explored to enrich this territory. Urothelial carcinoma is a veritable 'jungle' of therapeutic choices, where treatment individualisation and identification of new pathways to circumvent current pitfalls and improve outcomes. The largely unexplored zones of testicular germ cell and penile cancers suggest novel targets and complementary strategies to improve treatment. With several immunotherapies in routine clinical use for genitourinary cancer patients, immunotherapy has a solid footing, and many opportunities to explore new ideas and combinations to change the landscape of cancer immunotherapy and open new frontiers.
- Subject
- metastatic diseases; immune responses; combination immunotherapy; cancer immunotherapy
- Identifier
- http://hdl.handle.net/1959.13/1405385
- Identifier
- uon:35482
- Identifier
- ISSN:0311-306X
- Language
- eng
- Reviewed
- Hits: 943
- Visitors: 937
- Downloads: 0
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format |
|---|